• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

继发于胰腺癌的微小病变性肾病经化疗改善。

Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy.

机构信息

Department of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan.

Department of Nephrology, Shonan Kamakura General Hospital, Japan.

出版信息

Intern Med. 2021 Jan 15;60(2):251-257. doi: 10.2169/internalmedicine.5499-20. Epub 2020 Sep 19.

DOI:10.2169/internalmedicine.5499-20
PMID:32963158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7872799/
Abstract

We herein describe an 82-year-old patient who presented with proteinuria and systemic edema. He was diagnosed with minimal change disease (MCD) and was found to have stage III pancreatic cancer. He could not undergo surgical resection due to invasion to the celiac artery and he was thus treated with chemotherapy. After a month of chemotherapy, his proteinuria improved to a normal level. After two months of chemotherapy, computed tomography indicated a partial response to the therapy. MCD can occur as paraneoplastic syndrome in patients with malignant disease, and chemotherapy can be effective for MCD associated with paraneoplastic syndrome.

摘要

我们在此描述了一位 82 岁的患者,其表现为蛋白尿和全身水肿。他被诊断为微小病变病(MCD),并发现患有 III 期胰腺癌。由于肿瘤侵犯腹腔动脉,他无法进行手术切除,因此接受了化疗。化疗一个月后,他的蛋白尿恢复正常水平。化疗两个月后,计算机断层扫描显示对治疗有部分反应。MCD 可作为恶性肿瘤患者的副瘤综合征发生,化疗对与副瘤综合征相关的 MCD 可能有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/406425f1d3b5/1349-7235-60-0251-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/ecb3044ae356/1349-7235-60-0251-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/a59b23dfa75d/1349-7235-60-0251-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/89955662ad13/1349-7235-60-0251-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/8cf96e1ca5b6/1349-7235-60-0251-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/5eff5d3ae7dc/1349-7235-60-0251-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/fdf534522f5e/1349-7235-60-0251-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/d0eab013a1b2/1349-7235-60-0251-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/406425f1d3b5/1349-7235-60-0251-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/ecb3044ae356/1349-7235-60-0251-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/a59b23dfa75d/1349-7235-60-0251-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/89955662ad13/1349-7235-60-0251-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/8cf96e1ca5b6/1349-7235-60-0251-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/5eff5d3ae7dc/1349-7235-60-0251-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/fdf534522f5e/1349-7235-60-0251-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/d0eab013a1b2/1349-7235-60-0251-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ff7/7872799/406425f1d3b5/1349-7235-60-0251-g008.jpg

相似文献

1
Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy.继发于胰腺癌的微小病变性肾病经化疗改善。
Intern Med. 2021 Jan 15;60(2):251-257. doi: 10.2169/internalmedicine.5499-20. Epub 2020 Sep 19.
2
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.白蛋白结合型紫杉醇联合吉西他滨治疗胰腺癌
N Engl J Med. 2014 Jan 30;370(5):478-9. doi: 10.1056/NEJMc1314761.
3
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.白蛋白结合型紫杉醇联合吉西他滨治疗胰腺癌
N Engl J Med. 2014 Jan 30;370(5):478. doi: 10.1056/NEJMc1314761.
4
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.白蛋白结合型紫杉醇联合吉西他滨治疗胰腺癌
N Engl J Med. 2014 Jan 30;370(5):479-80. doi: 10.1056/NEJMc1314761.
5
Pancreatic cancer: standing on the shoulders of mice, making an iMPACT on pancreatic cancer.胰腺癌:站在小鼠的肩膀上,对胰腺癌产生重大影响。
Nat Rev Clin Oncol. 2013 Dec;10(12):665. doi: 10.1038/nrclinonc.2013.209. Epub 2013 Nov 5.
6
New option for the initial management of metastatic pancreatic cancer?转移性胰腺癌初始治疗的新选择?
J Clin Oncol. 2014 Aug 10;32(23):2405-7. doi: 10.1200/JCO.2013.54.4155. Epub 2014 Jun 30.
7
The winning formulation: the development of paclitaxel in pancreatic cancer.优胜配方:紫杉醇在胰腺癌中的研发。
Clin Cancer Res. 2013 Oct 15;19(20):5572-9. doi: 10.1158/1078-0432.CCR-13-1356. Epub 2013 Aug 5.
8
Minimal-change nephropathy associated with pancreatic carcinoma.与胰腺癌相关的微小病变性肾病
Arch Intern Med. 1988 Apr;148(4):975-6.
9
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.在经过大量预处理的胰腺癌患者中使用低剂量nab-紫杉醇为基础的联合化疗。
J Formos Med Assoc. 2020 Jan;119(1 Pt 1):97-105. doi: 10.1016/j.jfma.2019.01.015. Epub 2019 Mar 7.
10
Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer.肝动脉灌注化疗治疗胰腺癌标准化疗后肝转移。
Intern Med. 2021 Jan 15;60(2):223-229. doi: 10.2169/internalmedicine.5449-20. Epub 2020 Sep 19.

引用本文的文献

1
Minimal change glomerular disease associated with solid neoplasms: a systematic review.与实体肿瘤相关的微小病变肾小球疾病:一项系统综述
J Nephrol. 2025 Mar;38(2):343-352. doi: 10.1007/s40620-024-02084-6. Epub 2024 Oct 1.
2
Prostate Cancer Associated with Minimal Change Disease: A Case Report.与微小病变病相关的前列腺癌:一例报告
Glomerular Dis. 2022 May 13;2(3):145-150. doi: 10.1159/000525040. eCollection 2022 Jul.

本文引用的文献

1
Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.与恶性胸膜间皮瘤相关的微小病变病:病例报告及文献综述
BMJ Case Rep. 2016 Dec 19;2016:bcr2016217958. doi: 10.1136/bcr-2016-217958.
2
Minimal Change Disease.微小病变性肾病。
Clin J Am Soc Nephrol. 2017 Feb 7;12(2):332-345. doi: 10.2215/CJN.05000516. Epub 2016 Dec 9.
3
Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases.与非霍奇金淋巴瘤相关的微小病变肾病综合征:18例回顾性研究
Medicine (Baltimore). 2014 Nov;93(24):350-358. doi: 10.1097/MD.0000000000000206.
4
The treatment of minimal change disease in adults.成人微小病变病的治疗。
J Am Soc Nephrol. 2013 Apr;24(5):702-11. doi: 10.1681/ASN.2012070734. Epub 2013 Feb 21.
5
Glomerular diseases seen with cancer and chemotherapy: a narrative review.与癌症和化疗相关的肾小球疾病:叙述性综述。
Kidney Int. 2013 Jul;84(1):34-44. doi: 10.1038/ki.2012.484. Epub 2013 Jan 30.
6
Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.肾病综合征相关血栓栓塞疾病的流行病学和病理生理学。
Clin J Am Soc Nephrol. 2012 Mar;7(3):513-20. doi: 10.2215/CJN.10131011. Epub 2012 Feb 16.
7
Malignant pleural mesothelioma with associated minimal change disease and acute renal failure.恶性胸膜间皮瘤伴相关微小病变性肾病和急性肾衰竭。
Ren Fail. 2010;32(8):1012-5. doi: 10.3109/0886022X.2010.502275.
8
Minimal-change nephrotic syndrome preceding Hodgkin lymphoma by 5 years with expression of tumor necrosis factor alpha in Hodgkin-Reed-Sternberg cells.5 年前表现为微小病变性肾病综合征,随后发生霍奇金淋巴瘤,霍奇金-里德-斯特恩伯格细胞中表达肿瘤坏死因子-α。
Hum Pathol. 2010 Aug;41(8):1196-9. doi: 10.1016/j.humpath.2010.01.021.
9
Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome.初始激素治疗反应时间是特发性肾病综合征的一个主要预后因素。
J Pediatr. 2010 Jun;156(6):965-971. doi: 10.1016/j.jpeds.2009.12.020. Epub 2010 Mar 10.
10
Adult minimal-change disease: clinical characteristics, treatment, and outcomes.成人微小病变病:临床特征、治疗及预后
Clin J Am Soc Nephrol. 2007 May;2(3):445-53. doi: 10.2215/CJN.03531006. Epub 2007 Apr 11.